Abbott received approval from the FDA to market Humira as a treatment for reducing symptoms and inducing and maintaining clinical remission in adults with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Humira is also indicated for reducing the signs and symptoms and inducing clinical remission in these patients if they no longer respond to or are intolerant to infliximab, the only other approved biologic for treatment of Crohn&#82...